Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Omega-3 wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Probably helps
18 of 27 studies with measurable effects showed benefit.
Top outcomes
Verdict
Likely helps
3 of 3 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (1)
Outcomes where both Omega-3 and Pygeum have evidence — compare verdict strength side-by-side.
2-3g combined EPA+DHA daily
With meals containing fat
Triglyceride form fish oil
100-200mg standardized extract daily
Once or twice daily, With or without food
Standardized extract (13-14% sterols)
4-8 weeks
2-4 weeks
Immediate
4-12 weeks
6-8 weeks
6-8 weeks
8-12 weeks
Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
The New England journal of medicine (2019) · Rct · n=25871
During a median follow-up of 5.3 years, a major cardiovascular event occurred in 386 participants in the n-3 group and in 419 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.80 to 1.06; P=0.24).
Omega-3 fatty acids for intermittent claudication
The Cochrane database of systematic reviews (2024) · Meta analysis · n=1830
Omega-3 compared with a control may have little to no effect on ankle-brachial index (MD -0.02, 95% CI -0.08 to 0.04; 3 studies, 168 participants; very low-certainty evidence).
A systematic review and meta-analysis of the omega-3 fatty acids effects on brain-derived neurotrophic factor (BDNF)
Nutritional neuroscience (2024) · Meta analysis · n=587
The present systematic review and meta-analysis indicate the efficacy of omega-3 FAs in increasing the serum concentration of BDNF.
What do we know about phytotherapy of benign prostatic hyperplasia?
Life sciences (2015) · Systematic review
On the basis of preclinical studies several mechanisms of action have been postulated, including 5alpha-reductase inhibition, alpha-adrenergic antagonism, dihydrotestosterone and estrogen receptor inhibition.
Phytotherapy of benign prostatic hyperplasia. A minireview
Phytotherapy research : PTR (2014) · Systematic review
Histological BPH, which typically develops after the age of 40 years, ranges in prevalence from >50% at 60 years to as high as 90% by 85 years of age.
Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS)
BMJ clinical evidence (2011) · Systematic review
We found 63 systematic reviews, RCTs, or observational studies that met our inclusion criteria.
Based on multiple meta-analyses showing EPA-dominant formulas >1g/day most effective. Effects plateau around 2-2.5g. Adjunctive use with antidepressants shows better outcomes than monotherapy.
Based on Cochrane review (n=1562) and network meta-analysis showing modest benefits. Evidence quality noted as low-to-moderate due to dated methodology in available RCTs. Most studies used standardized bark extract.
AI-estimated from published studies. Interpret as directional guidance.
Omega-3 has a higher evidence score (9/10 vs 5.5/10) and wins in 2 of 3 categories.
For reduce inflammation, Omega-3 has a higher relevance score (90 vs 50).
No known interactions between Omega-3 and Pygeum have been documented in our database. However, always consult a healthcare provider before combining supplements.